TRANSCODE THERAPEUTICS, INC.

Insiders TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
0.6162 ^USD	-56.30%		-24.36%	-90.65%

04-22	Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI
04-22	Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	03-28	CI
TransCode Reports Additional Restructuring Steps; Chief Executive Michael Dudley to Retire	01-12	MT
TransCode Therapeutics, Inc. Announces CEO Changes	01-12	CI
TransCode Therapeutics, Inc. Announces Management Changes	01-12	CI
TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board	08/09/22	CI
TransCode Therapeutics, Inc. Appoints Zdravka Medarova as Chief Technology Officer	30/09/21	CI
TransCode Therapeutics : Names Zdravka Medarova as Chief Technology Officer	30/09/21	MT
TransCode Therapeutics Announces Key Appointments	18/02/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer